Ignite Creation Date:
2024-05-06 @ 10:21 AM
Last Modification Date:
2024-10-26 @ 12:28 PM
Study NCT ID:
NCT03230318
Status:
COMPLETED
Last Update Posted:
2023-12-19
First Post:
2017-07-24
Brief Title:
Derazantinib in Subjects With FGFR2 Gene Fusion- Mutation- or Amplification- Positive Inoperable or Advanced Intrahepatic Cholangiocarcinoma
Sponsor:
Basilea Pharmaceutica
Organization:
Basilea Pharmaceutica
Key Dates - Follows AllAPIJSON File Order
Start Date:
2017-09-28
Start Date Type:
ACTUAL
Primary Completion Date:
2022-10-25
Primary Completion Date Type:
ACTUAL
Completion Date:
2022-10-25
Completion Date Type:
ACTUAL
First Submit Date:
2017-07-24
First Submit QC Date:
July 24 2017
Study First Post Date:
2017-07-26
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
2023-12-19
Results First Post Date Type:
ACTUAL
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2023-11-29
Last Update Post Date:
2023-12-19
Last Update Post Date Type:
ACTUAL